PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance.
[BACKGROUND] Adaptor-related protein complex 1 subunit mu 2 (AP1M2) has been has been shown to be overexpressed in breast cancer tissues.
APA
Cui R, Chen H, et al. (2026). PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance.. Gene, 987, 150031. https://doi.org/10.1016/j.gene.2026.150031
MLA
Cui R, et al.. "PBX1-mediated transcription of AP1M2 promotes triple-negative breast cancer malignant progression and docetaxel resistance.." Gene, vol. 987, 2026, pp. 150031.
PMID
41621605
Abstract
[BACKGROUND] Adaptor-related protein complex 1 subunit mu 2 (AP1M2) has been has been shown to be overexpressed in breast cancer tissues. However, whether AP1M2 regulates triple-negative breast cancer (TNBC) progression and chemoresistance is unknown.
[METHODS] The expression of AP1M2 and pre-B-cell leukaemia homeobox 1 (PBX1) was analyzed by qRT-PCR or western blot. Cell proliferation, migration, invasion, docetaxel resistance, and apoptosis were analyzed using CCK8 assay, colony formation assay, EdU assay, transwell assay, wound healing assay and flow cytometry. Dual-luciferase reporter assay was used to assess the interaction between AP1M2 and PBX1.
[RESULTS] AP1M2 had increased expression in TNBC cells, and its knockdown suppressed TNBC cell proliferation, migration, invasion, and enhanced docetaxel sensitivity. In terms of mechanism, PBX1 bound to AP1M2 promoter region to enhance its transcription. The rescue experiments revealed that overexpression of AP1M2 could abolish the suppressive effect of PBX1 knockdown on TNBC cell proliferation, migration, invasion, and docetaxel resistance.
[CONCLUSION] PBX1-mediated AP1M2 facilitates cell proliferation, migration, invasion, and docetaxel resistance to accelerate TNBC malignant behavior, providing a novel target for TNBC treatment.
[METHODS] The expression of AP1M2 and pre-B-cell leukaemia homeobox 1 (PBX1) was analyzed by qRT-PCR or western blot. Cell proliferation, migration, invasion, docetaxel resistance, and apoptosis were analyzed using CCK8 assay, colony formation assay, EdU assay, transwell assay, wound healing assay and flow cytometry. Dual-luciferase reporter assay was used to assess the interaction between AP1M2 and PBX1.
[RESULTS] AP1M2 had increased expression in TNBC cells, and its knockdown suppressed TNBC cell proliferation, migration, invasion, and enhanced docetaxel sensitivity. In terms of mechanism, PBX1 bound to AP1M2 promoter region to enhance its transcription. The rescue experiments revealed that overexpression of AP1M2 could abolish the suppressive effect of PBX1 knockdown on TNBC cell proliferation, migration, invasion, and docetaxel resistance.
[CONCLUSION] PBX1-mediated AP1M2 facilitates cell proliferation, migration, invasion, and docetaxel resistance to accelerate TNBC malignant behavior, providing a novel target for TNBC treatment.
MeSH Terms
Humans; Triple Negative Breast Neoplasms; Pre-B-Cell Leukemia Transcription Factor 1; Docetaxel; Drug Resistance, Neoplasm; Female; Cell Proliferation; Cell Line, Tumor; Cell Movement; Gene Expression Regulation, Neoplastic; Disease Progression; Apoptosis; Promoter Regions, Genetic; Antineoplastic Agents
같은 제1저자의 인용 많은 논문 (4)
- NTRK2 promotes malignant progression and paclitaxel resistance of lung adenocarcinoma through targeting MYC/ABCF1 axis.
- Prognostic and immunotherapeutic potential of disulfidptosis-associated signature in pancreatic cancer.
- Neurturin-induced activation of GFRA2-RET axis potentiates pancreatic cancer glycolysis via phosphorylated hexokinase 2.
- Efficacy and safety of the immune checkpoint inhibitor-radiotherapy combination in advanced/unresectable hepatocellular carcinoma: A systematic review and meta-analysis.